While a targeted therapeutic approach in MPAL/ALAL makes biological sense (and has been specifically proposed in R/R patients [55]), evidence for a role for FLT3 inhibitors in the management of MPAL/ALAL remains scant. Here, FLT3 is linked to mixed phenotype acute leukemia.